ATHE stock news · Alterity Therapeutics
Get alerts for ATHE
Follow Alterity Therapeutics (ATHE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ATHEAlterity Therapeutics shared its Q1 FY27 cash flow report, showing cash reserves and plans for a Phase 3 trial.
NeutralAlterity reported A$41.3 million in cash and raised about A$5.5 million, but issued shares and is still preparing its Phase 3 trial. The update does not clearly change its outlook.
12 health care stocks are changing a lot before the market opens on Friday.
NeutralAlterity Therapeutics' shares fell 8% before Friday's open. The article gives no business news to explain the move, so it does not change the company's outlook.
12 health care stocks changed a lot after the market closed on Wednesday.
NeutralAlterity Therapeutics had an 8.41% after-market increase but the article contains no business or product news, so the company's view stays the same.
Key US patent granted to Alterity Therapeutics for its primary asset.
NeutralAlterity Therapeutics has secured a crucial US patent for its lead drug candidate ATH434, which is set to enter Phase 3 trials for Multiple System Atrophy. This patent not only strengthens the company's intellectual property position but also extends its commercial runway, potentially leading to significant market opportunities in treating neurodegenerative diseases.